Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals reports news about its clinical-stage biotechnology business and its strategy to build a neurology and oncology pipeline. Company updates commonly address anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system, including TPI 287 and Berubicin, as well as clinical-data presentations and regulatory-development planning.
Recurring developments also include executive leadership changes, pipeline prioritization, business-development strategy, financial results, capital-allocation commentary, shareholder voting matters, governance updates and capital-structure disclosures tied to its Nasdaq-listed common stock.
CNS Pharmaceuticals (NASDAQ: CNSP) announced the shipment of its Active Pharma Ingredient (API) for Berubicin to Pharmaceutics International, Inc. and BSP Pharmaceuticals. This milestone is crucial for the preparations for the upcoming Phase 2 trial for treating glioblastoma multiforme (GBM), expected to commence in Q4 2020. The company has adopted a dual manufacturing strategy to mitigate COVID-19 related risks. CNS holds a global exclusive license for Berubicin, which previously showed a 44% disease control rate in a completed Phase 1 trial.
CNS Pharmaceuticals announced the engagement of Berry Consultants to assist in designing its Phase 2 trial for the lead drug candidate, Berubicin. The CEO, John Climaco, expressed confidence in Berry Consultants' expertise, emphasizing the importance of their innovative approach. Berubicin aims to treat glioblastoma multiforme (GBM), an aggressive brain cancer, following a Phase 1 trial that showed a 44% disease control rate. The Phase 2 trial is expected to commence in Q4 2020, alongside a partner's trials in Poland for pediatric GBM patients.
CNS Pharmaceuticals, focused on treatments for brain cancers, announced that CEO John Climaco will present at the Life Sciences Investor Forum on June 25, 2020, from 12:30 PM to 1:00 PM ET. This online event will allow investors to ask questions in real-time, with an archived webcast available later. CNS is advancing Berubicin, its lead drug candidate, for treating GBM, a fatal brain cancer, and expects to initiate a Phase 2 trial later this year. Investors can pre-register for the event here.